| Ling, Yang Ya |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Shen, Lin |
TQB2450-III-08, NCT04809142: A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer |
|
|
| Recruiting | 3 | 392 | RoW | TQB2450 Injection, Anlotinib hydrochloride, Oxaliplatin injection, Capecitabine tablets, Gemcitabine hydrochloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Biliary Cancer | 03/22 | 02/23 | | |
NCT04300114: A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy |
|
|
| Terminated | 3 | 5 | RoW | Fluzoparib, SHR3162, Placebo | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Pancreatic Cancer | 02/22 | 02/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
NCT04222114: Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis |
|
|
| Recruiting | 3 | 282 | RoW | Catumaxomab, The treatment of investigator choice | LintonPharm Co.,Ltd. | Stomach Neoplasms | 03/23 | 08/23 | | |
NCT05015621: A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma |
|
|
| Recruiting | 3 | 194 | RoW | Surufatinib plus Toripalimab, HMPL-012 plus JS001, 5-fluorouracil, Calcium folinate and Irinotecan, FOLFIRI | Hutchison Medipharma Limited | Advanced Neuroendocrine Carcinoma | 05/25 | 05/25 | | |
FG-M108-04, NCT06177041: M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. |
|
|
| Recruiting | 3 | 486 | RoW | M108 monoclonal antibody, Placebo, Oxaliplatin, Capecitabine | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Locally Advanced Unresectable or Metastatic Gastric Cancer, Locally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma | 01/27 | 04/27 | | |
COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma |
|
|
| Active, not recruiting | 3 | 610 | RoW | AK104, Oxaliplatin, Capecitabine, Placebo | Akeso | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 08/24 | 04/25 | | |
NCT06304974: A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 488 | RoW | BL-B01D1, Irinotecan, paclitaxel, docetaxel | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Esophageal Squamous Cell Carcinoma | 05/26 | 05/26 | | |
NOTABLE-308, NCT06343116: Nimotuzumab Combined With Trifluridine/Tipiracil in the Treatment of Refractory Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 3 | 420 | NA | Nimotuzumab injection, Taixinsheng, Placebo, Trifluridine/tipiracil | Biotech Pharmaceutical Co., Ltd. | Refractory Metastatic Colorectal Cancer | 04/27 | 04/27 | | |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
AK109-301, NCT06341335: A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 506 | RoW | cadonilimab, AK104, pulocimab, AK109, paclitaxel, placebo | Akeso | Gastric and Gastroesophageal Junction Adenocarcinoma | 11/26 | 07/27 | | |
G-HOPE-001, NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Enrolling by invitation | 3 | 450 | RoW | irinotecan, IBI343, paclitaxel | Innovent Biologics (Suzhou) Co. Ltd. | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
HLX22-GC-301, NCT06532006: A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer |
|
|
| Recruiting | 3 | 550 | Japan, RoW | HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine | Shanghai Henlius Biotech, Henlius USA | Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer | 06/27 | 09/28 | | |
NCT04233151: QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety |
|
|
| Recruiting | 3 | 590 | RoW | QL1203, Placebo, mFOLFOX6 regimen | Qilu Pharmaceutical Co., Ltd. | Metastatic Colorectal Cancer | 12/24 | 07/25 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
NCT06086457: PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer |
|
|
| Recruiting | 3 | 436 | RoW | Radiation, Modern intensity modulated radiotherapy, TP or PF regimen depended on investigator's choice., Chemotherapy, PD-1 inhibitor, Camrelizumab | Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Peking University Cancer Hospital & Institute, Beijing Cancer Prevention & Treatment Society, Hebei Medical University Fourth Hospital, Tianjin Medical University Cancer Institute and Hospital, Fujian Cancer Hospital, Anyang Tumor Hospital, The First Affiliated Hospital with Nanjing Medical University, Sichuan Cancer Hospital and Research Institute, Tengzhou Central People's Hospital, The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital Xi'an Jiaotong University, Second Affiliated Hospital of Xi'an Jiaotong University, Affiliated Hospital of North Sichuan Medical College, Changzhou Cancer Hospital of Soochow University, Henan Cancer Hospital | Esophageal Neoplasms | 06/26 | 08/29 | | |
| Not yet recruiting | 3 | 165 | RoW | TQB3454 tablets, TQB3454 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Biliary Carcinoma | 12/26 | 12/26 | | |
NCT04848753: Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Active, not recruiting | 3 | 663 | RoW | Toripalimab combined with cisplatin and paclitaxel, Placebo combined with cisplatin and paclitaxel | Shanghai Junshi Bioscience Co., Ltd. | Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | 05/27 | 05/27 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
NCT03992911: Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma |
|
|
| Recruiting | 2/3 | 336 | RoW | Simmtecan, 5-FU and l-LV, FOLFSIM regimen, Toripalimab, JS001, Etoposide, Cisplatin, EP regimen, Etoposide, Carboplatin, EC regimen | Peking University | Neuroendocrine Carcinoma of the Bladder | 06/22 | 06/23 | | |
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy |
|
|
| Recruiting | 2/3 | 90 | RoW | Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
NCT05980481: A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 2/3 | 130 | RoW | RC48-ADC, Disitamab Vedotin, Trastuzumab Injection, Trastuzumab, Toripalimab, JS001, Oxaliplatin injection, Oxaliplatin, Capecitabine, Capecitabine Tablets | RemeGen Co., Ltd. | Gastric Cancer | 07/24 | 07/25 | | |
NCT05019794: Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations |
|
|
| Recruiting | 2a | 80 | RoW | Infigratinib, BGJ398 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Solid Tumor | 12/22 | 12/23 | | |
|
NCT03567629: Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 130 | RoW | Irinotecan, fluorouracil / calcium folinate, Capecitabine, S1, Bevacizumab, Cetuximab, Oxaliplatin | Peking University, Liaoning Tumor Hospital & Institute, Zhejiang University | mCRC | 12/21 | 12/23 | | |
NCT04705519: Nab-paclitaxel Combined With Bevacizumab in the Treatment of Metastatic Neuroendocrine Carcinoma |
|
|
| Recruiting | 2 | 100 | RoW | Nab-paclitaxel Combined With Bevacizumab | Peking University, Qilu Pharmaceutical Co., Ltd. | Neuroendocrine Carcinoma | 01/22 | 01/24 | | |
SEARCH-01, NCT04521179: Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors |
|
|
| Completed | 2 | 102 | RoW | KN026 combination, IO therapy | Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Peking University | HER2-positive Solid Tumors | 01/22 | 05/23 | | |
NCT04880811: Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification |
|
|
| Not yet recruiting | 2 | 43 | RoW | Afatinib, Toripalimab | Peking University | Esophageal Squamous Cell Carcinoma | 10/22 | 05/23 | | |
2019-012-00CH1, NCT04169672: Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors |
|
|
| Completed | 2 | 248 | RoW | Surufatinib, HMPL-012, Toripalimab, JS001 | Hutchison Medipharma Limited | Advanced Solid Tumors | 02/23 | 02/23 | | |
NCT04723030: The Transformation of Locally Advanced Pancreatic Cancer. |
|
|
| Not yet recruiting | 2 | 30 | RoW | carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound) | Peking University | Locally Advanced Pancreatic Cancer | 04/23 | 04/23 | | |
NCT05030246: Trial of Surufatinib Combined With Toripalimab in the Treatment of Peritoneal Metastatic Carcinoma of Gastrointestinal or Primary Peritoneal Cancer |
|
|
| Recruiting | 2 | 72 | RoW | Surufatinib/Toripalimab, HMPL-012/JS001 | Peking University | Refractory Metastatic Digestive System Carcinoma, Primary Peritoneal Cancer | 04/23 | 07/23 | | |
NCT06206278: Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma |
|
|
| Terminated | 2 | 6 | RoW | Infigratinib, BGJ398, BBP-831 | LianBio LLC | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 05/24 | 05/24 | | |
NCT05386056: Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 54 | RoW | Pembrolizumab, MK-3475, Sinoporphyrin Sodium, DVDMS, Photodynamic therapy, PDT | Peking University | Esophageal Squamous Cell Carcinoma | 10/23 | 06/24 | | |
NCT05022654: SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma. |
|
|
| Recruiting | 2 | 40 | RoW | SI-B001, Irinotecan | Sichuan Baili Pharmaceutical Co., Ltd. | Esophageal Squamous Cell Carcinomas | 06/25 | 06/25 | | |
| Recruiting | 2 | 200 | RoW | KN035 | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumor | 12/24 | 12/25 | | |
NCT06222944: Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA |
|
|
| Not yet recruiting | 2 | 90 | RoW | Anlotinib, Anlotinib Hydrochloride Capsule, TQB2450, Albumin-Bound Paclitaxel, Paclitaxel (albumin-bound), Paclitaxel for injection(Albumin Bound) | Peking University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Gastric Cancer, Adenocarcinoma of Esophagogastric Junction | 08/25 | 08/26 | | |
NCT05165407: Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC |
|
|
| Recruiting | 2 | 40 | RoW | Sintilimab, IBI310, Surufatinib, HMPL-012 | Peking University | Neuroendocrine Neoplasm | 03/24 | 03/25 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT04891198: ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 2 | 126 | RoW | Envafolimab | 3D Medicines (Sichuan) Co., Ltd. | Solid Tumor | 08/27 | 04/28 | | |
NCT05866510: Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer |
|
|
| Recruiting | 2 | 47 | RoW | Utidelone and anlotinib | Peking University, Beijing Biostar Pharmaceuticals Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Esophageal Cancer | 04/24 | 04/24 | | |
| Not yet recruiting | 2 | 360 | RoW | QLS31905, Oxaliplatin, Capecitabine, Gemcitabine, Cisplatin, QL1706, Chemotherapy drug | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 06/26 | 12/27 | | |
| Recruiting | 2 | 38 | RoW | PD1/PDL1 antibody monotherapy, up to 24 weeks, Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks, Radical surgery | Peking University | Gastric Cancer, Colon Cancer, MSI-H, DMMR Cancer | 06/29 | 06/29 | | |
NCT05628857: A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor |
|
|
| Recruiting | 2 | 240 | RoW | RC108 | RemeGen Co., Ltd. | Digestive Cancer | 10/24 | 10/25 | | |
NCT05818982: To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC |
|
|
| Recruiting | 2 | 72 | RoW | Afatinib, Irinotecan | Peking University | Advanced Esophageal Squamous Cell Carcinoma | 02/25 | 02/26 | | |
NCT04923932: Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients |
|
|
| Recruiting | 2 | 75 | RoW | Savolitinib, hmpl-504 | Hutchison Medipharma Limited | Gastric Cancer, Esophagogastric Junction Disorder | 04/25 | 10/25 | | |
|
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
NCT06008054: A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors |
|
|
| Recruiting | 2 | 376 | RoW | SI-B003, BL-B01D1, PD-1 Monoclonal Antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Esophageal Cancer, Gastric Cancer, Colorectal Cancer | 12/25 | 12/25 | | |
| Recruiting | 2 | 300 | RoW | Sacituzumab Govitecan-hziy, IMMU-132, Trodelvy™, GS-0132 | Gilead Sciences | Solid Tumor | 12/25 | 12/25 | | |
| Recruiting | 2 | 200 | RoW | Tislelizumab (BGB-A317) | BeiGene | MSI-H/dMMR Solid Tumors | 11/26 | 09/27 | | |
| Not yet recruiting | 2 | 80 | RoW | KN026, KN046, XELOX | Peking University Cancer Hospital & Institute | HER2-positive Colorectal Cancer, HER2-positive Biliary Tract Cancer | 12/26 | 12/26 | | |
NCT06099821: KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade |
|
|
| Recruiting | 2 | 39 | RoW | KN046, Regorafenib, Apatinib | Peking University Cancer Hospital & Institute | Digestive System Cancers | 12/26 | 12/26 | | |
NCT05985109: KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 98 | RoW | KN046, regorafenib | Peking University Cancer Hospital & Institute | Colorectal Cancer | 12/26 | 12/26 | | |
| Completed | 1/2 | 65 | RoW | CS3007 (BLU-285) | CStone Pharmaceuticals, Blueprint Medicines Corporation | Gastrointestinal Stromal Tumors | 04/20 | 04/23 | | |
|
|
NCT03565003: A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China |
|
|
| Completed | 1/2 | 126 | RoW | JAB-3068 | Jacobio Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors | 01/23 | 01/23 | | |
NCT04988191: Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer |
|
|
| Recruiting | 1/2 | 44 | RoW | Toripalimab, Bevacizumab, Irinotecan | Peking University | Colorectal Carcinoma | 06/23 | 12/23 | | |
AK109-201, NCT04982276: A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 1/2 | 138 | RoW | AK109, paclitaxel, AK104 | Akeso | Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | 10/25 | 01/27 | | |
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 114 | RoW | TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer | 09/24 | 12/24 | | |
NCT05139082: Study of CDK4/6 Inhibitor Combined With PD-L1 Monoclonal Antibody in the Treatment of PD-1/PD-L1 Resistance and Abnormal Cell Cycle Digestive System Tumors |
|
|
| Not yet recruiting | 1/2 | 60 | RoW | TQB3616 capsules＋ TQB2450 injection | Peking University | Digestive System Tumors | 10/23 | 10/23 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT06157827: A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma |
|
|
| Recruiting | 1/2 | 178 | RoW | LBL-024 for Injection, LBL-024, Etoposide Injection, Etoposide, Carboplatin Injection, Carboplatin, Atezolizumab injection, Atezolizumab, Cisplatin injection, Cisplatin | Nanjing Leads Biolabs Co.,Ltd | Advanced Neuroendocrine Carcinoma | 11/26 | 07/27 | | |
ORIN1001-C1, NCT05154201: Treatment of Patients with Advanced Solid Tumors with Oral Agent ORIN1001 and in Combination with Standard of Care. |
|
|
| Completed | 1/2 | 150 | RoW | ORIN1001 | Orinove, Inc., Fosun Pharma | Effect of Drug | 01/23 | 01/23 | | |
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 320 | RoW | TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab | Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb | Advanced Cancer | 02/25 | 05/25 | | |
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853 |
|
|
| Recruiting | 1/2 | 254 | US, RoW | HH2853 Tablets | Haihe Biopharma Co., Ltd. | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT06464055: A Study of GQ1010 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 220 | RoW | Dose Escalation, Dose Expansion1, Dose Expansion2, phase II | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Advanced Malignant Solid Tumors | 05/28 | 12/28 | | |
NCT06378593: A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations |
|
|
| Recruiting | 1/2 | 130 | RoW | 3HP-2827 | 3H (Suzhou) Pharmaceuticals Co., Ltd. | Solid Tumors With FGFR2 Alterations, Adult | 06/28 | 06/28 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
| Recruiting | 1/2 | 396 | RoW | LBL-024 for Injection, LBL-024 | Nanjing Leads Biolabs Co.,Ltd | Advanced Solid Tumor | 12/26 | 12/26 | | |
NCT05176665: EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers |
|
|
| Recruiting | 1/2 | 152 | US, RoW | EMB-01, FIT-013a | Shanghai EpimAb Biotherapeutics Co., Ltd., Labcorp Corporation of America Holdings, Inc | Neoplasms, Neoplasm Metastasis, Metastatic Gastrointestinal Carcinoid Tumor | 12/25 | 12/25 | | |
NCT05964543: The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors |
|
|
| Recruiting | 1/2 | 72 | RoW | Q-1802 Injection,Oxaliplatin Injection,Capecitabine, Q-1802,Oxaliplatin Injection,Xeloda | QureBio Ltd. | Gastroesophageal Junction (GEJ) Adenocarcinoma | 08/24 | 08/25 | | |
NCT05383482: Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 |
|
|
| Active, not recruiting | 1/2 | 22 | RoW | Afuresertib, LAE002, Nab paclitaxel, Docetaxel, Sintilimab | Laekna Limited | Solid Tumor, NSCLC, Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Gastric and Gastroesophageal Junction Adenocarcinoma | 06/24 | 12/25 | | |
NCT05508659: A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 128 | NA | Duvelisib, COPIKTRA, SG001, Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumors | 09/24 | 03/25 | | |
NCT05315167: A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 267 | RoW | PRJ1-3024 | Zhuhai Yufan Biotechnologies Co., Ltd | Advanced Solid Tumor, Advanced Solid Malignancies | 05/27 | 11/27 | | |
NCT04632108: A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1/2 | 214 | RoW | ASKB589 Injection | Jiangsu Aosaikang Pharmaceutical Co., Ltd., Jiangsu Aosaikang Biomedicine Co. LTD. | Malignant Solid Tumor | 12/24 | 12/25 | | |
| Recruiting | 1/2 | 725 | RoW | JSKN003 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Solid Tumor | 12/24 | 12/26 | | |
|
NCT05830097: A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 260 | US, RoW | CBP-1019, CBP-1019 for injection | Coherent Biopharma (Hefei) Co., Ltd. | Cancer, Breast, Cancer, Lung, Cancer of Pancreas, Cancer of Esophagus, Cancer Colorectal | 06/25 | 09/25 | | |
NCT05518045: Study of LM-108 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours |
|
|
| Enrolling by invitation | 1/2 | 392 | RoW | LM-108, Toripalimab | LaNova Medicines Limited | Advanced Solid Tumor | 07/25 | 10/25 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
NCT06008925: Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer |
|
|
| Recruiting | 1/2 | 43 | RoW | Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)), VG161, Nivolumab Injection, OPDIVO | CNBG-Virogin Biotech (Shanghai) Ltd. | Metastatic Gastric Cancer | 12/25 | 06/26 | | |
NCT05167448: A Study of ES104 in Patients With Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 1/2 | 58 | RoW | ES104 | Elpiscience (Suzhou) Biopharma, Ltd. | Metastatic Colorectal Cancer | 05/26 | 07/26 | | |
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
| Completed | 1 | 134 | RoW | CAR-CLDN18.2 T-Cells, Chimeric Antigen Receptor T Cells Targeting Claudin18.2, PD-1 Monoclonal Antibody, Toripalimab, Chemotherapy | Peking University, CARsgen Therapeutics Co., Ltd. | Advanced Solid Tumor | 03/21 | 01/24 | | |
| Completed | 1 | 42 | RoW | 10 mg/kg Q2W, MSB2311 10 Q2W, 20 mg/kg Q3W, MSB2311 20 Q3W | Suzhou Transcenta Therapeutics Co., Ltd. | Advanced Solid Tumor | 01/22 | 01/22 | | |
NCT04130763: Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of Anti- PD-1 |
|
|
| Completed | 1 | 10 | RoW | FMT capsule | Peking University | Gastrointestinal System Cancer | 02/23 | 01/24 | | |
NCT04689100: Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 259 | RoW | JMT101, FOLFIRI(Irinotecan, Leucovorin Calcium, and Fluorouracil); mFOLFOX6((Oxaliplatin, Leucovorin Calcium, and Fluorouracil);, FOLFIRI; mFOLFOX6; Irinotecan; | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumor | 12/21 | 06/22 | | |
NCT03713905: Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors |
|
|
| Completed | 1 | 293 | RoW | GLS-010, Recombinant Human Anti-PD-1 Monoclonal Antibody | Guangzhou Gloria Biosciences Co., Ltd. | Advanced Solid Tumors | 02/22 | 02/22 | | |
NCT06239623: ERK Inhibitor JSI-1187 in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 60 | RoW | JSI-1187 | JS InnoPharm, LLC | Solid Tumor, NSCLC, Melanoma | 09/24 | 12/24 | | |
NCT04973098: Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma |
|
|
| Recruiting | 1 | 13 | RoW | CT0181 Cells, CT0181 humanized anti GPC3 autogenous T Cell injection | Peking University, CARsgen Therapeutics Co., Ltd. | Advanced Hepatocellular Carcinoma | 08/22 | 06/23 | | |
NCT04040699: KN026 Combined With KN046 in Subjects With HER2 Positive Solid Tumor |
|
|
| Completed | 1 | 48 | RoW | KN026 combined with KN046 | Peking University, Jiangsu Alphamab Biopharmaceuticals Co., Ltd | HER2 Positive Solid Tumor | 09/22 | 12/23 | | |
TQB3811-I-01, NCT05046847: A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3811 Tablets in Patients With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 30 | RoW | TQB3811 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Solid Tumor | 10/22 | 12/22 | | |
| Recruiting | 1 | 206 | RoW | SHR-1701 | Jiangsu HengRui Medicine Co., Ltd. | Solid Tumor | 12/22 | 12/22 | | |
| Recruiting | 1 | 96 | RoW | TQB3454 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor or Hematologic Tumor | 12/22 | 12/22 | | |
NCT04906473: Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 109 | NA | KY100001 | Kunming Pharmaceuticals, Inc. | Advanced Solid Tumor | 12/22 | 10/23 | | |
| Recruiting | 1 | 104 | RoW | QLS31905 | Qilu Pharmaceutical Co., Ltd. | Advanced Solid Tumors | 12/22 | 12/23 | | |
NCT03603951: A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms |
|
|
| Active, not recruiting | 1 | 272 | RoW | SHR2554, EZH2 Inhibitor | Jiangsu HengRui Medicine Co., Ltd., Peking University Cancer Hospital & Institute | Relapsed or Refractory Mature Lymphoid Neoplasms | 02/26 | 08/26 | | |
WEE1, NCT04768868: The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 350 | US, RoW | IMP7068 | Impact Therapeutics, Inc., Covance | Advanced Solid Tumors | 04/23 | 08/23 | | |
NCT05393986: Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors |
|
|
| Recruiting | 1 | 63 | RoW | CT048 Autologous Injection (CT048), CT048 Autologous CAR T-cell Injection | Peking University, CARsgen Therapeutics Co., Ltd. | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/23 | 12/24 | | |
NCT04740398: A Study of CBP-1008 in Patients With Advanced Solid Tumor |
|
|
| Recruiting | 1 | 143 | RoW | CBP-1008 | Coherent Biopharma (Suzhou) Co., Ltd. | Advanced Solid Tumor | 09/24 | 09/24 | | |
